McKesson Corporation found using ticker (MCK) now have 14 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 460 and 320 calculating the mean target price we have 422.43. Given that the stocks previous close was at 383.47 this would indicate that there is a potential upside of 10.2%. The day 50 moving average is 377.9 and the 200 day moving average is 348.29. The company has a market capitalisation of $53,654m. You can visit the company’s website by visiting: https://www.mckesson.com
The potential market cap would be $59,106m based on the market concensus.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
